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Postmenopausal population is at increased risk of musculoskeletal impairments. Sarcopenia and osteoporosis are associated
with signiﬁcant morbidity and social and health-care costs. These two conditions are uniquely linked with similarities in
pathophysiology and diagnostic methods. Uniform diagnostic criteria for sarcopenia are still evolving. Postmenopausal sarcopenia
and osteoporosis share many environmental risk- and preventive factors. Moreover, geriatric frailty syndrome may result from
interaction of osteoporosis and sarcopenia and may lead to increased mortality. The present paper reviews the factors in evolution
of postmenopausal sarcopenia and osteoporosis.
1.Introduction
One of the biggest challenges for public health care is the
maintenance of health, independence, and mobility as well
as prevention and postponement of disability of the aging
population [1]. There are sex dependent diﬀerences in
morbidityanddisabilityamongtheelderlypopulationwhich
become more evident with age [2, 3]. Among middle-
agedwomen,menopausaltransition,causedbyphysiological
exhaustion of ovarian function [4, 5], evokes increase in
musculoskeletal, cardiovascular, and mental impairments
and cancer [6–8]. This increased female vulnerability related
to aging, together with predominance of female elderly
population,makesthemanimportanttargetforresearchand
preventive health care measures [7].
Sarcopenia, that is, muscle wasting, and osteoporosis,
that is, fragile bone disease, are signiﬁcant health burdens
among the postmenopausal women. The prevalence of sar-
copenia has been reported to be 10% to 40% in post-
menopausal population depending on the reference method
used and the population [8]. Osteoporosis aﬀects approx-
imately 30% of female population over 50 years [9]. Sar-
copenia results in decline in activities of daily living, quality
of life, and self-rated health and increases falls and related
skeletal fractures [10–15] which have been estimated to have
deep impact of social and healthcare-related costs of the
postmenopausal population [16–19].
The present paper focuses on similarities in acquired
factors associated with postmenopausal osteoporosis and
sarcopenia concentrating on decades after the menopausal
transition. Consequently, essential aspects on the eﬀects of
aging on sarcopenia and osteoporosis will be covered.
2. Contemporary Deﬁnition of
SarcopeniaandOsteoporosis
Evaluation of the evidence behind the synergism between
postmenopausal sarcopenia and osteoporosis requires a
clear deﬁnition for both conditions. Unfortunately, uniform
criteria for sarcopenia are still evolving, and methods as
well as diﬀerent measurement cutoﬀs have been used across
studies. Majority of the diagnostic thresholds for sarcopenia
have been developed based on muscle mass measurements
with similar methods applied for diagnosis of osteoporosis.
Moreover, the diagnosis of osteoporosis has shifted from2 Journal of Osteoporosis
salience of DXA towards independent risk factors for osteo-
porosis.
2.1. Sarcopenia. Among the elderly, genetics, hormonal
changes, and lifestyle factors related to physical activity
and nutritional factors have been linked to development of
sarcopenia. From physiologic viewpoint, these lead to alter-
ations in muscle protein turnover, muscle tissue remodeling,
loss of alpha motor neurons, muscle cell recruitment, apop-
tosis, and muscle’s fat content [20–22]. The multifactorial
etiologyofsarcopeniaemphasizesanddiﬀerentiatesthethree
divisions of sarcopenia, that is, muscle mass, muscle strength,
and muscle function. Conceptually, this is supported by the
evidencethatmusclestrengthdoesnotcorrelatedirectlywith
muscle mass, and the relationship between strength may not
belinear[23,24].Infact,somehaveargued,thatwithregards
to terminology, dynapenia would be a better acronym to
describe age-related decline in muscle strength and function
[25].This, however,hasnot yet beenuniformlyincorporated
into clinical use.
Sarcopenia is a syndrome characterized by progressive
and generalized loss of skeletal muscle mass and strength
with a risk of adverse outcomes related to physical ability,
quality of life, or even death [23, 26]. According to the
consensus of the European Working Group on Sarcopenia
in Older People (EWGSOP), sarcopenia may be categorized
into presarcopenia ( l o s so fm u s c l em a s s ) ,sarcopenia (loss of
muscle mass and strength or functional ability), and severe
sarcopenia (loss of muscle mass, strength, and functional
ability)[20].Thiscategorizationmaybeconsideredclinically
sound and holistically aligns the concept of multiple facets of
muscle wasting.
There are several methods for assessment of muscle
mass, strength, and function. Muscle mass may accurately be
assessed by dual X-ray absorptiometry (DXA) with very low
radiation dose (1-2micro-Sieverts). The operational deﬁni-
tions of sarcopenia have generally used DXA-based skeletal
muscle mass index (SMI) [27]. Muscle mass below 2SD of
the mean of young reference population has been considered
pathognomic for sarcopenia. Other methods available for
assessment of muscle mass include bioimpedance analysis
(BIA) [28–31], magnetic resonance imaging (MRI), and
computed tomography (CT) [32, 33]. In addition, anthro-
pometric measurements, such as calf circumference, arm
circumference, and skin fold thickness, may be used for
evaluation of muscle mass [27, 34].
Muscle strength may be measured by variety of methods.
Grip strength has been found to be a reproducible method
for assessment of muscle strength [35–37]. Isometric knee
extensor strength has also been commonly used for assess-
ment of muscle strength and has shown feasibility in frail
older subjects [38, 39], although there is limited reference
data available [40–42].
The international working group has recently recom-
mended a series of tasks, entitled short physical performance
battery (SPPB) as the standard evaluation of physical perfor-
mance in research and clinical use [43, 44]. Other physical
performance tests routinely used among the elderly include
gait speed [43], timed get-up-and-go test (TGUG) [45], stair
climb power test (SCPT) [46].
2.2. Osteoporosis. Osteoporosis aﬀects approximately 30%
of the postmenopausal population. Osteoporosis is charac-
terised by reduced bone mineral density (BMD) [47–51]a n d
increased rate of bone loss [52]. The main determinants of
BMD are the peak bone mass achieved by early adulthood,
the bone loss associated with age, and menopause in women
[53, 54]. Although the risk of fractures is greater among
women with low BMD, it explains only part of the increased
fracture tendency among the elderly [55]. This suggests that
also other BMD-independent risk factors should be taken
into account while evaluating the risk of fragility fractures
[56]. The pathophysiology behind osteoporosis is, as with
sarcopenia, multifactorial. Genetics, nutritional factors, life-
style factors, and comorbidities have been shown to be
associated with the disease [55–57]. In addition, factors
related to falls have independent role in development of
fragility fractures.
By deﬁnition, osteoporosis is a disease of increased
skeleton fragility accompanied by low BMD and microar-
chitectural deterioration [58]. The golden standard for mea-
suring bone material properties in clinical practice is axial
DXA measurement from femur and spine. Bone mineral
density (BMD) lower than −2.5SD below the young adults
is considered osteoporotic and BMD between −1a n d−2.5
osteopenic. Peripheral methods, for example, peripheral
quantitative computed tomography (pQCT) for assessment
of bone microarchitectural properties, have been developed,
but they have not supplanted central DXA as diagnostic
method.
3. Interaction betweenPostmenopausal
SarcopeniaandOsteoporosis: The Potential
Role of Common AcquiredRisk Factors
Sarcopenia and osteoporosis have been thought to coexist
[59]. Several studies have shown a positive association
between lean mass and BMD in postmenopausal women
[60–62]. Appendicular skeletal muscle-mass-related relative
skeletal muscle mass index (RSMI), which has been used for
deﬁnition of sarcopenia, has been suggested to be positively
related to BMD [63]. The correlation of RSMI with BMD,
however, may be signiﬁcantly aﬀected by diﬀerences in
physical activity [63]. Nevertheless, the positive association
between sarcopenia and osteoporosis has not been shown
constantly across diﬀerent studies [64]. Classically, it has
been suggested that changes in bone mass are mediated
through interaction with muscle strain via the sensory
functionofosteocytes[65].Thismechanostattheoryhasalso
emphasizedthesubstantialroleofestrogenincontrollingthe
muscle-bone unit which makes postmenopausal women an
especial target of interest. Consequently, there seem to be
several factors that signiﬁcantly contribute to the interaction
between sarcopenia and osteoporosis.
The evidence behind the synergism between sarcopenia
and osteoporosis should be viewed from the perspective ofJournal of Osteoporosis 3
the three modalities of sarcopenia, that is, muscle mass,
strength, and function and the two modalities of osteoporo-
sis, that is, BMD and fractures. Essentially, this interaction
shouldalsobeconsideredfromtheviewofcommonetiologic
risk- and preventive factors. Indeed, many such factors are
closely related to menopausal transition and age group of
the postmenopausal population. The following paragraph
concentrate on the common etiologic factors excluding
secondary factors related to speciﬁc morbidities.
3.1. Genetics. Muscle and bone tissues have common mes-
enchymal precursor [66, 67]. During the growth, bone
and muscle tissues exert signiﬁcant allometry [68, 69].
Thereafter, during the adulthood, the functional properties
between the two components of musculoskeletal system are
functionally closely associated, and bone loss as well as
muscle strength are positively correlated [70]. In the late
years of the lifespan, the loss of both muscle and bone tissue
shows parallel decline and may have genetic control [66, 71].
There are several gene candidates involved in the genetic
control of musculoskeletal interactions [72–74] which are
holistically reviewed in detail recently [69]. However, the
whole process of maturation, development, and decline
of musculoskeletal system is signiﬁcantly aﬀected, besides
genetics, by environmental factors [75].
The heritability of lean mass, measured with DXA, has
been estimated to vary between 56% and 84% [76, 77].
With regards to muscle strength and power, genetic eﬀects
explain 30%–50% in postmenopausal age group [77, 78].
Analogously,theheritabilityofbonestrength,measuredwith
section modulus of femoral neck, has been reported to be
40 to 55% [76]. Lean mass and areal BMD seem to have
common genetic eﬀects that contribute to the interaction
between these traits [76, 79]. This association is likely to
be multigenetic. A recent study found that muscle cross-
sectional area and structural bone strength share genetic
eﬀects in the postmenopausal age group [80].
To conclude, components of muscle and bone strength are
signiﬁcantlycontrolled by genes. Furthermore, bone andmuscle
strength may essentially share genetic eﬀects.
3.2. Aging and Hormonal Changes in Menopause. Peak mus-
cle strength is achieved in the early 40s after which muscle
strength gradually declines [81, 82]. After the age of 50, mus-
cle mass has been reported to decline 1-2% per year [83]a n d
musclestrength1.5%to3%peryear[84–87].Elderlywomen
lose muscle performance more rapidly than do their male
counterparts [88, 89]. It has been estimated that the decline
of muscle strength attributable to the menopause accounts
for an approximately 10–15% extraloss in addition to that
purely related to age [88, 89] .T h el o s so fm u s c l es t r e n g t h
during the menopause has been linked to estrogen depletion
[90, 91], evoked by exhaustion of ovarian function during
theperimenopausalyears.Plasmaestroneandestradiollevels
have been reported to be associated with muscle mass in
women [92]. This eﬀect may be mediated directly through
estrogen receptors in skeletal muscle [93] or indirectly
through the eﬀects of proinﬂammatory cytokines [94]. In
addition, it has been shown that hormone therapy maintains
muscle strength and performance [95–98] although this
aﬀect has not been observed constantly across studies [99,
100]. The natural menopausal transition seems, however,
not to accelerate the decline in functional ability (such as
get-up-and-go test or modiﬁed Cooper test) to the same
extent in comparison to muscle strength [88]. These ﬁndings
emphasize the diﬀerent roles of muscle mass, strength, and
function in development and evaluation of sarcopenia. In
addition to menopause-related female hormonal changes,
several other mechanisms, related to hormonal changes,
accumulation of free radicals, nutrition, and physical activity
among the others, may also contribute to sarcopenia in
aging population which partly occurs simultaneously with
menopause [91]. Consequently the exact contribution and
mechanism by which menopause aﬀects muscle tissue is still
not fully resolved.
Menopausal transition is the most important and
inevitable single factor in the evolution of postmenopausal
osteoporosis [53, 54]. At the beginning of menopause, the
acute loss of the restraining eﬀect of estrogen on receptors
on the membranes of osteoblasts and osteoclasts leads to
accelerated bone turnover, uncoupling bone formation from
resorption [101–103]. The closer molecular mechanisms of
estrogen-depletion-related bone loss have been linked to
the overproduction of bone resorptive cytokines (RANKL)
[103]. In addition, imbalance between calcium secretion
and absorption following the estrogen depletion has been
suggested to inﬂuence the accelerated bone loss rate [104].
It has been shown that menopausal transition is associated
with both increased bone loss rate, reduced BMD, and
increased fracture incidence [105–110]. The phase of the
most accelerated bone loss takes place at the very beginning
of menopause (amenorrhea phase) after which the bone
loss rate becomes progressively diminished for several years
during the early postmenopause [105–111]. Some diﬀer-
ences have been observed in the pattern of menopausal bone
loss between diﬀerent skeletal sites which may be related
to the diﬀerent composition of these sites with respect to
cortical and trabecular bone [112, 113]. Perimenopausal
bone loss rates of over −2 percent/year in spinal and over
−1 percent/year in the femoral region have generally been
reported [105, 106, 110, 111, 114]. In postmenopausal
women, age-related bone loss continues at age-speciﬁc rate
after the initial fastening during the menopausal transition
[112]. In women over the age of 60 years, the risk of fracture
hasbeenshowntoincrease6%peryear[115].Thesigniﬁcant
role of female hormones for bone health is further supported
by the ﬁnding that HT prevents postmenopausal bone loss
and decreases the risk of fractures [116–120] with 34%
r e d u c t i o ni nv e r t e b r a la n d1 3 %r e d u c t i o ni nn o n v e r t e b r a l
fracture incidence [121].
To conclude, female hormones essentially regulate both
muscle and bone health during the postmenopause and
thus play signiﬁcant role in development of sarcopenia and
osteoporosis. These may be, to some extent, prevented by HT.
Aging aggravates the eﬀects of estrogen depletion on bone and
muscle loss.4 Journal of Osteoporosis
3.3. Body Weight and Composition. In postmenopausal age
group,thereisasigniﬁcantpositivecorrelationbetweenbody
weight, fat mass, lean tissue mass with BMD [70]. However,
t h e r ea r es o m es p e c i ﬁ cd i ﬀerences in response of muscle and
bone tissue to weight, weight change, and fatness.
In healthy young subject, bone and muscle grow in
harmony with weight increase because of gravity-stimulated
mechanoreceptors [122, 123]. However, being overweight
impairs physical activity in all age groups. High BMI has
been previously found to predict poorer quality of life
particularly in the areas of physical functioning and health
perceptions [124, 125]. Increase in BMI in postmenopausal
population is predominantly due to increase in fat mass
with signiﬁcantly lower contribution of lean mass [126].
The increased prevalence of functional limitations and
disability with increasing BMI has been repeatedly reported,
although the relative increase in muscle mass with increasing
BMI might explain some discrepancies between genders
[127–130]. The decline in physical activity due to obesity
may contribute to the development of sarcopenia [131].
In addition, the fat and muscle tissue may be inversely
controlled through certain metabolic pathways, including
inﬂammatory cytokines [132], insulin resistance [133, 134],
and eﬀects of growth hormone [135]. These factors may
result in condition termed “sarcopenic obesity” [136, 137].
The prevalence of sarcopenic obesity has been suggested to
b ea r o u n d4t o1 2p e r c e n t[ 136, 138]. Sarcopenic obesity has
beenproposed tobeassociatedwithdisabilityandfunctional
decline [138, 139]. Other studies, however, have linked this
disability to only obesity itself [138].
Weight loss has been suggested to contribute to the
development in sarcopenia in aging population although
it has been argued that, during weight change, a greater
proportion of lean mass than fat mass is conserved [140].
However, weight loss interventions combining adequate diet
and exercise have been suggested to improve muscle strength
and quality with simultaneous fat loss [141]. This also aligns
the conception that there is a tight connection between
adiposity and muscle function. Weight-loss-related bone loss
has been found to be reduced in postmenopausal subjects
with good muscle strength [142].
Body weight and weight changes are positively linked to
BMD and its changes in postmenopausal women. Weight
and weight increase are associated with the maintenance of
BMD and reduced bone loss whereas thinness and weight
loss lead to low BMD and enhanced bone loss in early
and later postmenopause [143–145]. In addition, high body
weight is a strong independent predictor of lower post-
menopausal fracture incidence, especially of the hip [146].
These eﬀects may partly be linked with fat-tissue-related
estrogen production [5]. It has been found that HT may
counteract weight-loss-related bone loss in postmenopausal
women, which supports the role of estrogen in fat-bone
interaction [147]. Mechanical load as such is likely to
lead to bone strengthening with mobility-induced weight-
bearing stress. In addition, hormones that regulate fat tissue
metabolism, leptins, have been suggested to be involved in
the regulation of bone metabolism [148, 149]. The heavier
population also has a higher nutritional intake and may
thus consume more calcium and other bone-preserving
products. In addition, the diﬀerentiating role of muscles and
fat in weight-related bone mass changes remains unclear.
It has been hypothesized that lower hip fracture incidence
among the obese is related to higher soft tissue padding,
not bone strength itself [150]. Indeed, increased fracture risk
in appendicular sites has been linked to obesity [150]. Part
of the observed BMD changes related to weight alterations
may be due to methodological diﬃculties encountered in
the measurement techniques adopted to deal with body
compositional factors, most importantly fat tissue [62, 151].
To conclude, fatness is related to higher lean and bone
mass, and weight loss generally causes bone and muscle loss in
postmenopausal age group. However, obese women may have
unique etiology behind sarcopenia (sarcopenic obesity) and
increasedriskofosteoporoticfractures(appendicularfractures).
3.4. Physical Activity and Exercise. Bone cross-sectional area
is associated with muscle cross-sectional area [152], and
lean mass correlates with areal BMD [153]. In addition,
muscle volume and estimated torque of muscles have been
suggested to explain diﬀerences in structural bone strength
[154].Consequently,thepositiveassociationbetweenmuscle
and bone tissue has been suggested to be a result of the forces
that muscles exert on the bones [155].
Inactivity is a well-demonstrated cause of signiﬁcant loss
of muscle mass and strength at all ages [156, 157]. Moreover,
there are diﬀerences in eﬀects of diﬀerent types of physical
activity with regards to response of muscle tissue. While
aerobic exercise contributes less to muscle hypertrophy in
comparison to resistance training, it has signiﬁcant impact
on protein synthesis, satellite cell activation, and increased
muscle ﬁber area [158–160]. Aerobic exercise may also
decrease the body fat inﬁltration of muscle tissue improving
the functional properties of muscle system relative to body
weight. Resistance training, however, signiﬁcantly improves
the muscle mass, strength, and their interaction in post-
menopausal age group [27, 161]. Interestingly, the eﬀects
of resistance training may have muscle-quality-improving
eﬀects even among the frail older population [162–168].
However, the amount of training, whether aerobic or
resistance type in nature, may need intensity more than
typical for leisure type of physical activity in order to have
signiﬁcant eﬀects [169]. From the clinical viewpoint, an
important facet of the eﬀects of exercise on muscle tissue
is that prevention of sarcopenia with exercise may not have
suﬃcient power to occur at short period of time, especially
among the elderly [170, 171]. Consequently, it is widely
accepted that prevention of sarcopenia should be carried out
throughout the lifespan.
It has been postulated that both decreasing muscle
activity and muscle mass are the main causes of bone loss
during aging [172]. Furthermore, in experimental models,
mature skeleton is less sensitive to exercise-induced peak
muscle strain than growing bone [173]. In adult bone
exercise most likely induces conservation rather than gains
in strength [174]. According to previous studies, muscle
strength, impact, and nonimpact exercise as well as the
overall physical activity level are positively associated withJournal of Osteoporosis 5
BMD, bone loss rate, and fracture risk [5, 62, 144–177].
Analogously, immobilization has been demonstrated to
accelerate bone loss rate [178]. Certain appendicular muscle
strength measures, most importantly grip strength, have
been demonstrated to correlate well with the overall muscle
performance and strength [35, 179]. Grip strength may
have diagnostic value for prediction of fractures [176]a n d
selection of patients to BMD measurements [180]. It has
been suggested, that in elderly women’s lean mass correlates
with BMD irrespective of body site but that the association
between muscle strength and BMD is site-speciﬁc [62].
Functional capacity has been shown to be associated
with higher BMD and predict fractures in postmenopausal
women [180, 181]. K¨ arkk¨ ainen et al. found that standing
on one foot (SOOF) less than 10 seconds increased the risk
of hip fracture 9-fold, and self-assessed ability to walk less
than 100m increased the risk of clinical vertebral fractures 4-
fold and hip fracture 11-fold in postmenopausal population
[181]. Moreover, a recent Cochrane review on the eﬀects of
exercise on preventing and treating postmenopausal osteo-
porosis concluded that especially weight-bearing exercise is
eﬀective in increasing BMD, although exercise seems not to
prevent fractures during the ﬁrst two years of therapy [182].
To conclude, muscle and bone strength are directly posi-
tively linked. Physical exercise has both muscle and bone tissue
maintaining capabilities in postmenopausal women.
3.5. Vitamin D. There are two forms of vitamin D, ergo-
calciferol (vitamin D2) and cholecalciferol (vitamin D3).
Cholecalciferol is the metabolically active form of vitamin D.
Vitamin D is produced with either the eﬀect of ultraviolet B
radiation or ingested with nutrition, and the metabolically
active form is produced in the kidneys.
Vitamin D receptor is present in skeletal muscle [183].
Vitamin D deﬁciency aﬀects predominantly weight-bearing
muscles of the lower limb [184, 185]. Previous studies have
shown that vitamin D levels are positively associated with
muscle power, function, and physical performance [186,
187]. Doses of 400IU vitamin D may not be suﬃcient
to improve muscle function in nondepleted population.
Nevertheless, in vitamin-D-deﬁcient subjects, vitamin D
400IU, with calcium 800mg, has been reported to improve
gait speed and body sway [188]. In the age group of the
postmenopausal population, vitamin D 800IU with calcium
1000mg has shown to improve muscle function [189, 190].
Patients with low 25(OH)D levels have been shown to have
impaired functional performance, psychomotor function,
muscle strength and increased falling tendency [191, 192].
Previously, vitamin D has been reported to improve postural
and dynamic balance [193]. Although it has been suggested
thatcalciumsupplementationisnecessaryforoptimalaction
of vitamin D [194], combined vitamin D with calcium is
superior to calcium alone in reducing the number of falls
[190]. In the postmenopausal age group, low vitamin D and
calcium intake and renal insuﬃciency may result in mild
secondary hyperparathyroidism [195]. Indeed, low vitamin
D and high parathyroid hormone levels have been found
to increase the risk of low muscle mass and strength in
postmenopausal population [195].
Vitamin D, combined to calcium, has been shown to
decrease bone loss in adults and the elderly [196]. It has
been postulated that serum 25(OH)D is a more important
predictor of hip BMD than calcium intake [197], and
correction of vitamin D hypovitaminosis has been demon-
strated to result in increases in BMD [198]. Nevertheless,
the protective eﬀects of vitamin D have not been showed
constantly [199], and, in postmenopausal women with
adequate vitamin D levels, calcium supplementation may be
as eﬀective as vitamin D [200]. A recent Cochrane review on
eﬀects of vitamin D and vitamin D analogues on prevention
fractures associated with involutional and postmenopausal
osteoporosis concluded that vitamin D alone is unlike to
prevent fractures while supplementation with calcium does
appear to prevent fracture in institutional care [201].
To conclude, vitamin D is essential in physiological-
processes-related muscle strength, function, and bone strength.
Vitamin D substitution may prevent fractures and functional
decline in postmenopausal women.
4.InteractiveConsequences of Osteoporosis
andSarcopenia:FallsandFrailtySyndrome
4.1.Falls. Animportantcommonconsequenceofsarcopenia
is tendency to fall which, together with osteoporosis, lead to
fragilityfractures.One-thirdofindividualsaged65andolder
fallatleastonceeachyear,andabouthalfofthesefalltwiceor
more [202, 203]. Of these falls 3–6% lead to fractures [202,
204]typicallydistalradius,proximalhumerus,andhip[205–
207]. Falls have complex and diverse causes. Maintenance of
posturerequiresvisual,tactile,proprioceptive,andvestibular
competence, central processing, and coordinated motor
response [208, 209]. Furthermore, ankle ﬂexibility, plantar
tactile sensation, and muscle strength have role in balance
[210]. In addition, there are several comorbidities and
medication that increase the risk of falling.
It has been shown that the upper and lower body
weakness is adversely related to falls [211]. Lower extremity
weakness is better predictor of falls than weakness of the
upper body. Moreover, several single-intervention strategies
for fall prevention have proven to be beneﬁcial. Strength and
balance training reduces both noninjurious and injurious
falls [212–217]. However, multifactorial fall prevention has
not been shown to have positive eﬀect constantly [218, 219].
There are two main determinants for fragility fractures:
bonematerialqualityandtendencytofall.Vertebralfractures
in the elderly population may occur without falls, while the
incidence of other fractures is dependent on the tendency
to fall. The most number of fragility fractures occur among
women without osteoporotic BMD [220] although the risk
of fracture is higher in women with low BMD. The risk
of falling has been more closely related with limb fracture
risk than BMD [221], and postmenopausal women with the
highest physical activity level may have moderately higher
wrist fracture incidence despite of lower bone loss rate
[222].
To conclude, falls are more frequent in sarcopenic subjects
and especially increase the functional decline among osteo-
porotic subjects.6 Journal of Osteoporosis
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Figure 1: Dimensions of postmenopausal sarcopenia, osteoporosis, and frailty syndrome.
4.2. Frailty Syndrome. By deﬁnition, central element deﬁn-
ing frailty is a state of great vulnerability of an aged subject
when confronted by a stressor. Components of sarcopenia
are substantially included into the concept of frailty among
the elderly. Frailty syndrome has been deﬁned as a clinical
syndromeinwhichthreeormoreofthefollowingcriteriaare
present: unintentional signiﬁcant weight loss, self-reported
exhaustion, weakness (measured with grip strength), slow
walking speed, and low physical activity [223]. Given this
frame, it has been postulated that sarcopenia and related
poor muscle strength limits mobility and physical activity
and thereby reduces total energy expenditure and nutritional
intake, which, in turn, lead to weight loss and further
aggravate sarcopenia [224]. Previous studies have indicated
thatthecomponentsofbothsarcopeniaandfrailtysyndrome
are signiﬁcant and independent risk factors of disability and
death [225, 226]. A recent study found a strong association
between this commonly used deﬁnition for the frailty
syndrome and lower extremity indexes of body composition
[226]. Frail’s older persons had lower muscle density and
muscle mass and higher fat mass. Moreover, in an analysis
of the single criterion composing the frailty score, physical
inactivity was the strongest correlate of body composition.
However, as with deﬁnition of sarcopenia, the uniform
criteria for frailty syndrome have not fully developed and
shouldbereassessedacrosspopulations.Furthermore,osteo-
porosis and bone fragility may be considered to further
aggrevate the consequences of frailty syndrome. Presently,
the criteria of frailty syndrome does not include assessment
of osteoporosis or BMD. However, previous studies have
shownassociationsbetweencomponentsofosteoporosisand
frailty syndrome [227] and have been reviewed thoroughly
recently [228]. Furthermore, a recent study by Frisoli et al.
has demonstrated, that osteoporosis plus sarcopenia have
concomitant impact on frailty status in elderly women [229].
It was found that, in the presence of both sarcopenia and
osteoporosis, the odds for frailty were over two times higher
(OR 6.4) than those in presence of either syndrome alone
(OR 3.1 for sarcopenia and OR 2.1 for osteoporosis). It
must be reminded, however, that clinically signiﬁcant frailty
generally occurs decades after the menopausal transition
itself.
To conclude, frailty syndrome presents the most aggravated
formofincreasedmorbidityamongsarcopenicplusosteoporotic
subjects.
5. Conclusions
Figure 1 summarizes the associations between postmeno-
pausal osteoporosis, sarcopenia, falls, and frailty syndrome.
Postmenopausal women are at risk of both osteoporosis
and sarcopenia. There is evidence that these two conditions
coexists and share similar risk factors. Both sarcopenia
and osteoporosis are strongly linked not only to aging
but also to estrogen depletion and thereby to menopausal
transition. This makes the postmenopausal population a
signiﬁcant target group for prevention of both sarcopenia
and osteoporosis.
While the associations between muscle strength, muscle
mass, and functional capacity with clinically relevant end-
point of osteoporosis, that is, BMD and fractures, have beenJournal of Osteoporosis 7
reported, there are no studies addressing the associations
between three stages of clinical sarcopenia, that is, presar-
copenia, sarcopenia, and severe sarcopenia. The associations
of the three modalities of sarcopenia with osteopenia,
osteoporosis, and severe osteoporosis remain unexplored.
An essential part of the diagnosis of both osteoporosis
and sarcopenia includes DXA, which allows simultaneous
assessment of both conditions. The future research should
concentrate on exploring the clinically relevant dimensions
and interactions of sarcopenia and osteoporosis.
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